Navigation Links
New studies examine elimination of hepatitis B and C
Date:4/1/2009

Two new studies in the April issue of Hepatology explore the ways that hepatitis B virus (HBV) and hepatitis C virus (HCV) can be cleared from patients' bodies. Hepatology is a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience (www.interscience.wiley.com).

Both HBV and HCV are global health problems. They can lead to cirrhosis and liver cancer and they cause millions of deaths each year. Treatments to contain or cure these infections have been difficult to find. Researchers continue to explore potential therapies and the immune system response to the diseases.

The first new study sheds light on the immunological response to coinfection with HBV and HCV. Researchers led by Evangelista Sagnelli of Naples, Italy, report that for patients with chronic HCV, HBV superinfection can lead to clearance of the HCV.

They compared 29 HCV patients to 29 people, matched by age, gender and risk factors, who did not have HCV. All of the patients developed acute HBV during the same time period. The patients with HCV were more likely to have a severe course of illness, and one died of liver failure. However, nearly a quarter (six out of 24) emerged HCV-free.

"Extensive acute hepatocellular necrosis, although life-threatening, may lead to a clearance of chronic HCV infection," the authors report. Still, the severity of acute HBV in HCV patients raises "the concern that this clinical event could become an emerging health care problem in countries with a wide spread of both HBV and HCV infection," they write.

"Further efforts should be made to extend the use of HBV vaccination in patients with chronic HCV infection" they also suggest.

The second study, headed by Maurizia Brunetto of Pisa, Italy, recommends interferon-based therapies as a first-line approach for patients with chronic HBV, because these have the best chance of clearing hepatitis B virus surface antigen (HBsAg). The reduction of HBsAg serum levels leading to HBsAg clearance is the hallmark of a newly achieved immune control of the infection by mean of a significant reduction of virus infected hepatocytes.

The researchers retrospectively investigated the relationship between treatment regimens and changing levels of HbsAg in 386 patients in a multinational study.

"Significantly more patients treated with peginterferon alfa-2a (21 percent) or peginterferon alfa-2a plus lamivudine (17 percent) achieved HBsAg levels under 100 IU/mL at the end of treatment compared with lamivudine (1 percent)," they report.

"HBsAg clearance represents the best possible and closest to cure outcome of antiviral therapy in patients with chronic hepatitis B, but is realistic almost exclusively among patients receiving interferon-based regimens, which are recommended as a first-line therapeutic approach," they conclude. Interferon therapy switches the chronic active hepatitis B patient in the non-active HBV carrier who lose serum HBsAg during the years after the end of therapy. If the case occurs before the development of liver cirrhosis it endows the patient with the same life expectancy of the non-HBV infected subject.


'/>"/>

Contact: Sean Wagner
medicalnews@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Gene Studies of Male-Female Differences Often Flawed
2. Two studies published in the Lancet
3. Study of Studies Finds No Risk to Children From Phthalates in Toys
4. Just Completed Studies Reveal Impact of New Medicare Reimbursement Regulations
5. Studies Prove Exercise Can Heal the Body Mind and Soul
6. Studies Shed New Light on Breast Cancer, Treatment
7. Multi-Year Compendium of Pharmaceutical Case Studies Available from Best Practices, LLC
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Mississippi (PRWEB) , ... January 19, 2017 , ... St. ... Siena Center. , Siena Center is a skilled nursing facility on the grounds of ... and semiprivate rooms. It recently was voted the best nursing home in Mississippi for ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the ... Medicine Associates of Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, ... Williams have each been chosen by their peers for the 2017 list based ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Connecticut Dermatology Group ... Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background ... , “It is with considerable pleasure to welcome back Dr. Kim to the CDG ...
(Date:1/19/2017)... California (PRWEB) , ... January 19, 2017 , ... ... paragraph styled text designs that will simplify the editing process for all media ... ProParagraph Basics is a package of 30 simplistically styled self-animating paragraphs designed for ...
(Date:1/19/2017)... , ... January 19, 2017 ... ... member of the American Osteopathic College of Proctology) announced today the opening ... throughout Southern California ( http://www.hemorrhoidsremovalcenterscalifornia.com ): Hemorrhoids Center of Los Angeles (Beverly ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Fla. , Jan. 19, 2017  Sensus ... medical device company specializing in the treatment of ... as keloids, with superficial radiation therapy, today announced ... full year 2016 financial results on Thursday, February 2, ... Company will hold a conference call with the ...
(Date:1/19/2017)... , January 19, 2017 ... Therapeutic Option to Address Motor Symptoms and Motor ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... Stocchi , European Neurological Review,2016;11(Suppl. 2): 2-15, ...
(Date:1/19/2017)... 2017 The Global Therapy Partnering Terms and ... partnering deals and agreements entered into by the world,s ... - Top deals by value - Deals listed by ... The report provides understanding and access to the ... leading healthcare companies. The report provides an analysis ...
Breaking Medicine Technology: